Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT

Pulmonary hypertension treatments continue to evolve and one very promising advancing treatment option is inhaled therapy which delivers medication directly to the lungs. The webinar speakers will discuss the current landscape and future of inhaled therapies in pulmonary hypertension, including:• Currently approved inhaled therapies.• Key differences between inhaled treatment options and the conditions they manage, […]

Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT Read Post »

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026

The Phase 2 CADENCE randomised controlled trial tested sotatercept in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH-HFpEF) — a serious condition with high mortality and no proven treatments (Group 2 WHO pulmonary hypertension classification). 164 patients received either sotatercept (at one of two doses) or placebo

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026 Read Post »

René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research

At the 66th Congress of the German Society for Pneumology in Munich, the €5,000 René Baumgart Foundation research prize was awarded to two outstanding researchers working in the field of pulmonary hypertension (full text in German available at this link) English AI translation and summary Dr. Fenja Knöpp (Justus Liebig University, Giessen) was recognised for

René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research Read Post »

TRANSLATE »
Scroll to Top